Transitioning from nanoflow to standard flow LC/MS: High throughput protein biomarker quantification for clinical research
Liquid chromatography-mass spectrometry-based proteomics has been widely used for protein biomarker discovery and validation. When transitioning from discovery proteomics to targeted protein biomarker quantification, the MRM-based LC/MS method plays an important role in clinical research. To ensure analytical reproducibility and robustness, implementing a standard flow-based triple quadrupole LC/MS system has a tremendous benefit when involving a large cohort.
Learning Objectives:
- Quantitative sensitivity, precision, and accuracy of standard flow-based dynamic MRM method for targeted protein biomarker analysis using the Agilent 6495 LC/TQ
- Successful transfer of PromarkerD method for diabetic kidney disease research from nanoflow to standard flow
- When sample limited, a low flow LC system, Evosep One, coupled to Agilent 6495 LC/TQ could be used for high throughput studies
For Research Use Only. Not for use in diagnostic procedures.
Presenter: Linfeng Wu, Ph.D. (LC/MS Application Scientist, Agilent Technologies)
Dr. Linfeng Wu received her Ph.D. in 2007 at University of Connecticut for Biomedical Sciences. After a postdoctoral training in Dr. Michael Snyder’s group at Stanford University, she worked as a research scientist in biotech industry focusing on protein biomarker discovery and multi-omics integration in personalized medicine. Dr. Wu joined Agilent in 2015 as an application scientist, focusing on LC/MS-based protein, proteomics and small molecule analyses.
